Payment overview · 2025
General Payments
$607.62
23 reported records · 6 companies
Healthcare provider profile · identity verified
Dennis Stolpner, M.D.
Allopathic & Osteopathic Physicians|General Practice · SANTA ANA, CA · NPI 1497018782
Verified facts
What the public records show
CMS Open Payments records show Dennis Stolpner, M.D. received $607.62 in general payments during 2025 across 23 reported records.
Ardelyx, Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $240.20 | 39.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.40 | 29.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.40 | 12.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.54 | 7.5% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $37.84 | 6.2% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $28.24 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.62 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $240.20 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $76.40 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.25 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.01 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.54 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 199 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 59 |
| Clonidine Hcl | Clonidine Hcl | 186 | 71 |
| Gabapentin | Gabapentin | 160 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 48 |
| Metformin Hcl | Metformin Hcl | 140 | 41 |
| Allopurinol | Allopurinol | 128 | 39 |
| Losartan Potassium | Losartan Potassium | 122 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 36 |
| Azithromycin | Azithromycin | 90 | 74 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 88 | 25 |
| Baclofen | Baclofen | 86 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 31 |
| Dexlansoprazole Dr | Dexlansoprazole | 67 | 21 |
| Vascepa | Icosapent Ethyl | 67 | 19 |
| Lidocaine | Lidocaine | 63 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 19 |
| Nitroglycerin | Nitroglycerin | 60 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 17 |
| Furosemide | Furosemide | 57 | 18 |
| Famotidine | Famotidine | 54 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 22 |
| Ezetimibe | Ezetimibe | 52 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 14 |
| Carvedilol | Carvedilol | 50 | 14 |
| Lisinopril | Lisinopril | 47 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 19 |
| Sertraline Hcl | Sertraline Hcl | 46 | 11 |
| Finasteride | Finasteride | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 13 |
| Lorazepam | Lorazepam | 44 | 17 |
| Memantine Hcl Er | Memantine Hcl | 44 | 12 |
| Creon | Lipase/Protease/Amylase | 42 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 17 |
| Omeprazole | Omeprazole | 41 | 17 |
| Prednisone | Prednisone | 41 | 26 |
| Celecoxib | Celecoxib | 40 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Acyclovir | Acyclovir | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Eliquis | Apixaban | 32 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 27 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 12 |
| Clonazepam | Clonazepam | 26 | 12 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Linzess | Linaclotide | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 12 |
| Chlorthalidone | Chlorthalidone | 24 | 14 |
| Febuxostat | Febuxostat | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Trulance | Plecanatide | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Zileuton Er | Zileuton | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Tavaborole | Tavaborole | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Captopril | Captopril | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 17 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.62 · 23 records | Ardelyx, Inc. | BREZTRI, EVENITY, FARXIGA, Flector, IBSRELA, Licart, MOUNJARO, PANCREAZE, Tirosint, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error